The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing subjectivity into what should be an objective process.

In this video interview, David Morton, PhD, director of biostatistics at Certara, discusses how growing FDA support is accelerating the adoption of Bayesian approaches, enabling more flexible, ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...